Duncan McGregor, as the CEO and Founder of Cyclogenix Ltd, brings over three decades of invaluable experience in the biotechnology sector, particularly in antibody and protein engineering. His journey from a bench-level scientist to a senior management and board-level executive has equipped him with a...
Duncan McGregor, as the CEO and Founder of Cyclogenix Ltd, brings over three decades of invaluable experience in the biotechnology sector, particularly in antibody and protein engineering. His journey from a bench-level scientist to a senior management and board-level executive has equipped him with a profound understanding of the complexities involved in drug discovery and development. At Cyclogenix, Duncan is at the forefront of pioneering research focused on immuno-oncology, leveraging the innovative bispecific cylobody platform to create next-generation therapeutics.
Under his leadership, the company is exploring the unique properties of plant cyclotides—micro-proteins known for their stability and versatility—as scaffolds for drug discovery. This approach emphasizes not only the oral and blood-brain barrier (BBB) delivery of peptide and protein drugs but also the evaluation and modulation of cyclotide pharmacokinetics and pharmacodynamics (PK/PD). Duncan's strategic vision has been instrumental in advancing Cyclogenix's mission to develop novel immunotherapeutics that can significantly impact cancer treatment.
His previous role as Chief Scientific Officer (CSO) at a leading biotechnology firm laid the groundwork for his entrepreneurial venture, where he successfully concluded a research collaboration deal with Wyeth, showcasing his ability to forge strategic partnerships that drive innovation. With expertise in pre-clinical studies, phage display, and biopharmaceuticals, Duncan continues to resolve complex issues in drug development, ensuring that Cyclogenix remains at the cutting edge of the life sciences industry. His commitment to advancing therapeutic options through rigorous scientific inquiry and strategic thinking positions Cyclogenix as a key player in the evolving landscape of immuno-oncology.
